157 related articles for article (PubMed ID: 30030355)
1. Proceedings of the 2017 Viral Clearance Symposium, Session 1.2: Upstream Mitigation, Part 2-Virus Barrier Filter and HTST.
Chen D; Bolton G
PDA J Pharm Sci Technol; 2018; 72(5):462-469. PubMed ID: 30030355
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness of mouse minute virus inactivation by high temperature short time treatment technology: a statistical assessment.
Murphy M; Quesada GM; Chen D
Biologicals; 2011 Nov; 39(6):438-43. PubMed ID: 21985900
[TBL] [Abstract][Full Text] [Related]
3. Revisiting mouse minute virus inactivation by high temperature short time treatment.
Su J; Rice J; Hoffman J; Alvarado S; Bailey M; Kopp M; Murphy M; Kiss R; Barone PW; Wiebe ME; Springs SL; Dehghani H; Chen D
Biotechnol Bioeng; 2021 Aug; 118(8):2967-2976. PubMed ID: 33913515
[TBL] [Abstract][Full Text] [Related]
4. Proceedings of the 2017 Viral Clearance Symposium Session 5: Facility Risk Mitigation.
Ma J; Kreil TR
PDA J Pharm Sci Technol; 2018; 72(5):511-515. PubMed ID: 30030359
[TBL] [Abstract][Full Text] [Related]
5. Proceedings of the 2017 Viral Clearance Symposium, Session 1.1: Upstream Mitigation, Part 1-Cell Bank and Bulk Harvest Testing.
Bolton G; Chen D
PDA J Pharm Sci Technol; 2018; 72(5):455-460. PubMed ID: 30030351
[TBL] [Abstract][Full Text] [Related]
6. Proceedings of the 2019 Viral Clearance Symposium, Session 7: Cell Banks and U.S. Pharmacopeia.
O'Donnell S
PDA J Pharm Sci Technol; 2022; 76(4):358-361. PubMed ID: 34911823
[TBL] [Abstract][Full Text] [Related]
7. Susceptibility of mouse minute virus to inactivation by heat in two cell culture media types.
Schleh M; Romanowski P; Bhebe P; Zhang L; Chinniah S; Lawrence B; Bashiri H; Gaduh A; Rajurs V; Rasmussen B; Chuck A; Dehghani H
Biotechnol Prog; 2009; 25(3):854-60. PubMed ID: 19405099
[TBL] [Abstract][Full Text] [Related]
8. Proceedings of the 2017 Viral Clearance Symposium, Session 2.1: DSP Unit Operations-Virus Filtration/Inactivation.
Kreil TR; Roush D
PDA J Pharm Sci Technol; 2018; 72(5):470-478. PubMed ID: 30030356
[TBL] [Abstract][Full Text] [Related]
9. Risk Mitigation in Preventing Adventitious Agent Contamination of Mammalian Cell Cultures.
Shiratori M; Kiss R
Adv Biochem Eng Biotechnol; 2018; 165():75-93. PubMed ID: 29134459
[TBL] [Abstract][Full Text] [Related]
10. Review: High temperature short time treatment of cell culture media and feed solutions to mitigate adventitious viral contamination in the biopharmaceutical industry.
Djemal L; Fournier C; von Hagen J; Kolmar H; Deparis V
Biotechnol Prog; 2021 May; 37(3):e3117. PubMed ID: 33372404
[TBL] [Abstract][Full Text] [Related]
11. Identification and root cause analysis of cell culture media precipitates in the viral deactivation treatment with high-temperature/short-time method.
Cao X; Stimpfl G; Wen ZQ; Frank G; Hunter G
PDA J Pharm Sci Technol; 2013; 67(1):63-73. PubMed ID: 23385565
[TBL] [Abstract][Full Text] [Related]
12. Protection of biomanufacturing processes from virus contamination through upstream virus filtration of cell culture media.
Wieser A; Modrof J; Kreil TR
Biotechnol Bioeng; 2023 Oct; 120(10):2917-2924. PubMed ID: 37337932
[TBL] [Abstract][Full Text] [Related]
13. Proceedings of the 2019 Viral Clearance Symposium, Session 6: Virus-Retentive Filtration.
O'Donnell S; Bolton G
PDA J Pharm Sci Technol; 2022; 76(4):349-357. PubMed ID: 34911825
[TBL] [Abstract][Full Text] [Related]
14. Evolution of approaches to viral safety issues for biological products.
Lubiniecki AS
PDA J Pharm Sci Technol; 2011; 65(6):547-56. PubMed ID: 22294576
[TBL] [Abstract][Full Text] [Related]
15. Use of MMV as a Single Worst-Case Model Virus in Viral Filter Validation Studies.
Gefroh E; Dehghani H; McClure M; Connell-Crowley L; Vedantham G
PDA J Pharm Sci Technol; 2014; 68(3):297-311. PubMed ID: 25188350
[TBL] [Abstract][Full Text] [Related]
16. Proceedings of the 2017 Viral Clearance Symposium: Conclusion.
Hepbildikler S; Johnson S; Bluemel J
PDA J Pharm Sci Technol; 2018; 72(5):525-530. PubMed ID: 30030353
[TBL] [Abstract][Full Text] [Related]
17. Biopharmaceutical Industry Approaches to Facility Segregation for Viral Safety: An Effort from the Consortium on Adventitious Agent Contamination in Biomanufacturing.
Barone PW; Avgerinos S; Ballard R; Brussel A; Clark P; Dowd C; Gerentes L; Hart I; Keumurian FJ; Kindermann J; Leung JC; Ly N; Mink S; Minning S; Mullberg J; Murphy M; Nöske K; Parriott S; Shum B; Wiebe ME; Springs SL
PDA J Pharm Sci Technol; 2019; 73(2):191-203. PubMed ID: 30361281
[TBL] [Abstract][Full Text] [Related]
18. Proceedings of the 2017 Viral Clearance Symposium, Session 6: Ensuring Viral Safety in Continuous Processing.
Johnson SA; Roush D
PDA J Pharm Sci Technol; 2018; 72(5):516-524. PubMed ID: 30030352
[TBL] [Abstract][Full Text] [Related]
19. The Use of Bayesian Hierarchical Logistic Regression in the Development of a Modular Viral Inactivation Claim.
Banton D; Vacante D; Bulthuis B; Goldstein J; Wineburg M; Schreffler J
PDA J Pharm Sci Technol; 2019; 73(6):552-561. PubMed ID: 31101710
[TBL] [Abstract][Full Text] [Related]
20. Proceedings of the 2017 Viral Clearance Symposium, Session 4: Submission Strategies.
Schwantes A; Specht R; Chen Q
PDA J Pharm Sci Technol; 2018; 72(5):498-510. PubMed ID: 30030357
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
